Investigational drug · Phase 3
HLX07
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colon Cancer Adenocarcinoma, Squamous NSCLC, Advanced or Metastatic Squamous Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
17
Any phase or sponsor naming "HLX07"
First trial start
2025
Apr 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX07", any sponsor or status.
- Phase 215
Conditions studied
As listed on its trial records.
- Colon Cancer Adenocarcinoma
- Squamous NSCLC
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Carcinoma of Head and/or Neck
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX07" as an intervention, largest first.
- A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07318883 · 720 participants (planned) · Start Mar 2026 · Primary completion Jan 2031
Drug: HLX07; HLX07 placebo and 4 more · For: Squamous NSCLC
Sites: Guangzhou, China
- A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT07459751 · 706 participants (planned) · Start May 27, 2026 · Primary completion Jan 15, 2030
Drug: HLX43; HLX43+HLX07 and 1 more · For: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Sites: Beijing, China
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT06857279 · 167 participants (planned) · Start Apr 22, 2025 · Primary completion Dec 30, 2027
Drug: HLX43 DOSE 1; HLX43 DOSE 2 and 5 more · For: Carcinoma of Head and/or Neck
Sites: Jinan, China; Shanghai, China
- A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLCPivotal-lookingStatus unknown
Shanghai Henlius BiotechIndustry
NCT04976647 · 156 participants (planned) · Start Jan 18, 2022 · Primary completion Jan 30, 2023
Drug: HLX10+chemo; HLX10+HLX07+chemo and 1 more · For: Squamous Non-small-cell Lung Cancer
Sites: Guangzhou, China
- Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck TumorsPivotal-lookingStatus unknown
Shanghai Henlius BiotechIndustry
NCT04297995 · 131 participants (planned) · Start Jul 29, 2020 · Primary completion May 30, 2024
Drug: HLX10; HLX07 and 3 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Shanghai, China
- A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07358585 · 126 participants (planned) · Start Jan 31, 2026 · Primary completion Jul 28, 2027
Drug: HLX43 dose 1 + HLX07; HLX43 dose 2 + HLX07 and 2 more · For: Colon Cancer Adenocarcinoma
Sites: Guangzhou, China
Shanghai Henlius BiotechIndustry
NCT05513573 · 75 participants (planned) · Start Dec 14, 2022 · Primary completion Sep 30, 2024
Drug: HLX07; HLX10 and 2 more · For: Nasopharyngeal Carcinoma by AJCC V8 Stage
Sites: Guanzhou, China
Shanghai Henlius BiotechIndustry
NCT05221658 · 60 participants (planned) · Start Aug 25, 2022 · Primary completion Jun 30, 2024
Drug: HLX07+HLX10+ Cisplatin+5-FU; HLX07 · For: ESCC or Esophageal Adenosquamous Carcinoma
Sites: Beijing, China; Fuzhou, China; Xiamen, China · 17 sites in all
- A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR ExpressionStatus unknown
Shanghai Henlius BiotechIndustry
NCT05215925 · 60 participants (planned) · Start Feb 1, 2023 · Primary completion Jul 15, 2023
Drug: HLX07+carboplatin+pemetrexed; HLX07+docetaxel and 1 more · For: HLX07, nsqNSCLC, High EGFR Expression
Sites: Shanghai, China
- HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular CarcinomaStatus unknown
Shanghai Henlius BiotechIndustry
NCT05290220 · 60 participants (planned) · Start Aug 1, 2022 · Primary completion Dec 15, 2023
Drug: HLX07; HLX10 and 2 more · For: Advanced Hepatocellular Carcinoma
Newest research
PubMed records naming it or its code names, newest first.
- HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial.
Li C, Zeng K, Zhu D, et al. · Ther Adv Med Oncol 2026
- HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study.
Liu Y, Wang Y, Zhu Y, et al. · Cancer Commun (Lond) 2024
- Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy.
Lin PH, Tseng CL, Cheng YC, et al. · Expert Opin Biol Ther 2021
- Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.
Hou MM, Ho CL, Lin HY, et al. · Invest New Drugs 2021
Also in development for Colon Cancer Adenocarcinoma
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.